Cerevel Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2018-01-01

Employees: -

Market Cap: $8.1B

Website: https://www.cerevel.com/

Clinical Trials

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: [14C]-darigabat

First Posted Date: 2024-05-30

Last Posted Date: 2024-07-31

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 8

Registration Number: NCT06435923

Locations: 🇺🇸
Austin, Texas, Austin, Texas, United States

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Emraclidine
Drug: Esomeprazole

First Posted Date: 2024-04-15

Last Posted Date: 2024-07-24

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 20

Registration Number: NCT06366243

Locations: 🇺🇸
Dilworth, Minnesota, Dilworth, Minnesota, United States

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Emraclidine

First Posted Date: 2024-03-08

Last Posted Date: 2024-05-02

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 8

Registration Number: NCT06301971

Locations: 🇺🇸
Austin, Texas, Austin, Texas, United States

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Emraclidine
Drug: Itraconazole
Drug: Carbamazepine
Drug: Metformin

First Posted Date: 2023-07-28

Last Posted Date: 2024-04-02

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 60

Registration Number: NCT05965219

Locations: 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Phase 2

Recruiting

Conditions: Panic Disorder

Interventions: Drug: Placebo
Drug: Darigabat

First Posted Date: 2023-07-12

Last Posted Date: 2024-12-12

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 246

Registration Number: NCT05941442

Locations: 🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸
North Miami Beach, Florida, North Miami Beach, Florida, United States
🇺🇸
Orlando, Florida, Orlando, Florida, United States

and more 28 locations

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Phase 1

Recruiting

Conditions: Renal Impairment

Interventions: Drug: Emraclidine

First Posted Date: 2023-07-11

Last Posted Date: 2024-11-25

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 60

Registration Number: NCT05940402

Locations: 🇺🇸
Knoxville, Tennessee, Knoxville, Tennessee, United States
🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸
Tustin, California, Tustin, California, United States

and more 1 locations

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Phase 1

Recruiting

Conditions: Hepatic Impairment

Interventions: Drug: Emraclidine

First Posted Date: 2023-07-07

Last Posted Date: 2024-12-12

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 40

Registration Number: NCT05935033

Locations: 🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸
San Antonio, Texas, San Antonio, Texas, United States
🇺🇸
Orlando, Florida, Orlando, Florida, United States

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

First Posted Date: 2023-07-06

Last Posted Date: 2023-11-24

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 15

Registration Number: NCT05933187

Locations: 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Emraclidine

First Posted Date: 2023-06-23

Last Posted Date: 2023-11-24

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 16

Registration Number: NCT05915546

Locations: 🇺🇸
Dilworth, Minnesota, Dilworth, Minnesota, United States

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Darigabat
Drug: Carbamazepine

First Posted Date: 2023-04-21

Last Posted Date: 2023-08-03

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 13

Registration Number: NCT05824143

Locations: 🇺🇸
Orlando, Florida, Orlando, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy